Raul R Silva

Summary

Publications

  1. doi request reprint Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder
    Raul R Silva
    Academic Behavioral Center, New York, NY, USA
    Clin Neuropharmacol 36:117-21. 2013
  2. doi request reprint Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder
    Raul R Silva
    New York University Langone Medical Center, New York, NY, USA
    Clin Pediatr (Phila) 49:840-51. 2010
  3. doi request reprint Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder
    Raul R Silva
    New York University Child Study Center, NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA
    J Am Acad Child Adolesc Psychiatry 47:199-208. 2008
  4. ncbi request reprint Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder
    Raul R Silva
    New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    J Child Adolesc Psychopharmacol 16:239-51. 2006
  5. ncbi request reprint Critical assessment of the methylphenidate transdermal system
    Sharon Kowalik
    Division of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    Drugs Today (Barc) 43:515-27. 2007
  6. ncbi request reprint Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva
    Raul R Silva
    New York University School of Medicine, New York, New York, USA
    Drugs 66:1127-8; discussion 1128. 2006

Collaborators

Detail Information

Publications6

  1. doi request reprint Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder
    Raul R Silva
    Academic Behavioral Center, New York, NY, USA
    Clin Neuropharmacol 36:117-21. 2013
    ..This study aimed to compare the effects of dexmethylphenidate (D-MPH) extended-release (ER) 30 mg and D-MPH-ER 20 mg on attention, behavior, and performance in children with attention-deficit/hyperactivity disorder...
  2. doi request reprint Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder
    Raul R Silva
    New York University Langone Medical Center, New York, NY, USA
    Clin Pediatr (Phila) 49:840-51. 2010
    ..Obtaining a baseline electrocardiogram for any patient starting stimulant treatment is reasonable if access to such screening is readily available and not too costly...
  3. doi request reprint Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder
    Raul R Silva
    New York University Child Study Center, NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA
    J Am Acad Child Adolesc Psychiatry 47:199-208. 2008
    ..This study compared once-daily dexmethylphenidate extended release (D-MPH-ER) 20 mg/day and placebo over 12 hours in children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting...
  4. ncbi request reprint Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder
    Raul R Silva
    New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    J Child Adolesc Psychopharmacol 16:239-51. 2006
    ..The aim of this study was to assess changes in symptomatology of attention-deficit/ hyperactivity disorder (ADHD) with extended-release dexmethylphenidate (d-MPHER) versus placebo in a laboratory classroom setting...
  5. ncbi request reprint Critical assessment of the methylphenidate transdermal system
    Sharon Kowalik
    Division of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    Drugs Today (Barc) 43:515-27. 2007
    ..Efficacy was demonstrated at all time points measured in ADHD, from 2-12 hours. Most adverse events reported were mild to moderate in severity; the most frequent adverse events reported were disturbances in sleep and appetite...
  6. ncbi request reprint Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva
    Raul R Silva
    New York University School of Medicine, New York, New York, USA
    Drugs 66:1127-8; discussion 1128. 2006